A status report on the genome mapping race between the government funded Human Genome Project and the privately funded effort by Celera.

NASA officials have submitted a plan to Congress to give NASA authority to commercialize some services on the space shuttle, and keep the money it earned.

NASA looks to commercialization and entertainment opportunities to protect itself from the uncertainty of budgetary cycles.

Celera Genomics answers critics concerns that they are out to 'monopolize the genome'.

Biotechnology researchers met in San Francisco to discuss the implications of the biotechnology revolution over the next 20 years. They estimate that the biotechnology industry is where the internet was five years ago and that the same laws that led to the explosive growth of the internet, Moore's Law and Metcalfe's Law, will also accelerate the speed of progress in the biotech industry.

After the successful mapping of the human genome, researchers have shifted their focus to the new science of proteomics, the study of proteins. The new challenge is is developing tools to analyze proteins much more quickly than the current technology -- and making those tools economically viable.

Nuclear weapon research meets genomics in a collaboration to create a supercomputer big enough to solve perhaps the most complicated problem in all of science: the function of all human cells. Sandia National Laboratories, home of the world\'s largest supercomputer; Celera Genomics (CRA), which mapped the human genome; and Compaq, home of the alpha chip, signed the agreement Friday morning at the Department of Energy in Washington, D.C.

A sobering look at the challenges of detecting and defending against terrorists that use biological weapons.

Scientists have decoded the genome of the bubonic plague bacterium -- a possible bio-weapon, as well as an endemic disease in some countries.

The vaccine against anthrax is in the hands of a single company that is running out of money, hasn't gained FDA approval for the vaccine or its manufacturing facilities and hasn't produced a single dose of the vaccine since it took over production in 1998.